Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.
Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.
Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.
The antibody-drug conjugate improved progression-free and overall survival for patients with low HER2 expression on breast tumors.
A new type of treatment uses antibodies to deliver cancer-fighting drugs directly to tumors.
A new type of cancer treatment uses antibodies to deliver chemotherapy drugs directly to tumors.
There are many ways to get smarter in this issue.
A look back at some of the most important science and treatment news Cancer Health covered this year.
People who received the antibody-drug conjugate were also more likely to experience tumor remission.
Data from early clinical trials suggest new precision cancer treatments are on the horizon.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
The antibody-drug conjugate extended survival by four months compared with chemotherapy.
COVID-19, FDA drug approvals and new approaches to treatment and quality of life stood out among this year’s top stories.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.